KEY TAKEAWAYS
- The OReO phase III trial aimed to assess the benefits, safety, and best response to re-using PARPi drugs in Chinese OC patients.
- The result demonstrated that reusing PARP inhibitor drugs can be effective for treating OC, but there is a need to find better ways to identify which patients will benefit most from this treatment.
The OReO/ENGOT Ov-38 trial demonstrated enhanced progression-free survival (PFS) with maintenance olaparib rechallenge over placebo. Yet, the subpopulations deriving greater benefit from Poly (ADP-ribose) polymerase inhibitors (PARPi) rechallenge remain unclear.
So, for this study, researchers aimed to assess the benefits, safety, and best response to re-using PARPi drugs in Chinese ovarian cancer(OC) patients.
The study was conducted at 12 institutions from June 2019 to March 2023; patients with recurrent OC previously treated with PARPi were analyzed for demographics and outcomes upon rechallenge with PARPi as maintenance therapy or salvage treatment.
About 70 patients were included, with a median follow-up of 13.0 months. About 56 patients (80%,56/70) received PARPi as maintenance after maintenance therapy. Median progression-free survival (mPFS) was 10.6 months (95% CI, 7.1–12.0) with the first PARPi (PARPi1) and 8.6 months (95% CI, 5.3–13.0) with PARPi retreatment (PARPi2).
Of the patients, 32.1% (18/56) had BRCA1/2 mutations, and their PFS did not significantly differ from BRCA wild-type or unknown patients (BRCAm vs. BRCAwt or unknown, HR=0.997 [95% CI: 0.480–2.072], P=0.9935).
Among those rechallenged, 87.5% (39/56) switched to other PARPi, showing a numerically longer mPFS compared to those who did not switch (mPFS: 8.6 vs. 7.7 months; HR=0.820 [95% CI: 0.394–1.707], P=0.5958). 4.3% (3/70) discontinued PARPi2 due to adverse events(AEs), primarily hematologic AEs.
The result demonstrated that reusing PARP inhibitor drugs can be effective for treating OC, but there is a need to find better ways to identify which patients will benefit most from this treatment.
Source: https://ijgc.bmj.com/content/33/Suppl_3/A19
Clinical Trial: https://clinicaltrials.gov/study/NCT03106987
Li J, Shao F, Zhao L, Zheng F, Zhu H, Li E, Zhou W, Yao G, Liu J, Zheng J, Pan S, Zhang Y, Wu X. Multicenter real-world experiences of PARPi rechallenge in patients with ovarian cancer in China
